



**QUEEN'S
UNIVERSITY
BELFAST**

Lung clearance index: Evidence for use in clinical trials in cystic fibrosis

Kent, L., Reix, P., Innes, J. A., Zielen, S., Le Bourgeois, M., Braggion, C., Lever, S., Arets, H. G. M., Brownlee, K., Bradley, J. M., Bayfield, K., O'Neill, K., Savi, D., Bilton, D., Lindblad, A., Davies, J. C., Sermet, I., & De Boeck, K. (2014). Lung clearance index: Evidence for use in clinical trials in cystic fibrosis. *Journal of Cystic Fibrosis*, 13(2), 123-138. <https://doi.org/10.1016/j.jcf.2013.09.005>

Published in:
Journal of Cystic Fibrosis

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

© 2013 European Cystic Fibrosis Society

This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Review

Lung clearance index: Evidence for use in clinical trials in cystic fibrosis

L. Kent^{a,b}, P. Reix^c, J.A. Innes^{d,e}, S. Zielen^f, M. Le Bourgeois^g, C. Braggion^h, S. Leverⁱ,
H.G.M. Arets^j, K. Brownlee^k, J.M. Bradley^{a,b}, K. Bayfield^l, K. O'Neill^m, D. Saviⁿ, D. Bilton^o,
A. Lindblad^p, J.C. Davies^{l,o}, I. Sermet^{g,q},
K. De Boeck^{r,*}, On behalf of the European Cystic Fibrosis Society Clinical Trial Network
(ECFS-CTN) Standardisation Committee

^a Centre for Health and Rehabilitation Technologies (CHaRT), Institute for Nursing and Health Research, University of Ulster, Newtownabbey, UK

^b Regional Cystic Fibrosis Centre, Belfast Health and Social Care Trust, Belfast, UK

^c Centre de Référence de la Mucoviscidose, Hospices Civils de Lyon, Lyon, France

^d Scottish Adult Cystic Fibrosis Service, Western General Hospital, Edinburgh, UK

^e Molecular and Clinical Medicine, University of Edinburgh, UK

^f Department of Paediatrics, J.W. Goethe-Universität Frankfurt, Germany

^g Centre de Référence de la Mucoviscidose, Hôpital Necker-Enfants Malades, Paris, France

^h Cystic Fibrosis Center, Pediatric Department, Meyer Children's Hospital, Florence, Italy

ⁱ Erasmus MC, Rotterdam, The Netherlands

^j Department of Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Center Utrecht, The Netherlands

^k Children's Cystic Fibrosis Centre, Leeds Teaching Hospitals, Leeds, UK

^l Department of Gene Therapy, Imperial College London, UK

^m Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK

ⁿ Department of Pediatrics and Pediatric Neurology, Cystic Fibrosis Center, Sapienza University of Rome, Italy

^o Royal Brompton & Harefield NHS Foundation Trust, London, UK

^p Gothenburg CF Centre, Queen Silvia Children's Hospital, Göteborg, Sweden

^q Université Paris Descartes, Paris, France

^r Pediatric Pulmonology, University Hospitals Leuven and KU Leuven, Leuven, Belgium

Received 19 June 2013; received in revised form 10 September 2013; accepted 23 September 2013

Available online 5 December 2013

Abstract

The ECFS-CTN Standardisation Committee has undertaken this review of lung clearance index as part of the group's work on evaluation of clinical endpoints with regard to their use in multicentre clinical trials in CF.

The aims were 1) to review the literature on reliability, validity and responsiveness of LCI in patients with CF, 2) to gain consensus of the group on feasibility of LCI and 3) to gain consensus on answers to key questions regarding the promotion of LCI to surrogate endpoint status.

It was concluded that LCI has an attractive feasibility and clinimetric properties profile and is particularly indicated for multicentre trials in young children with CF and patients with early or mild CF lung disease. This is the first article to collate the literature in this manner and support the use of LCI in clinical trials in CF.

© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. Open access under [CC BY-NC-ND license](#).

Keywords: Clinimetric properties; Multiple breath washout; Lung clearance index; Outcome measures; Surrogate endpoints

* Corresponding author at: Pediatric Pulmonology, Dept. of Pediatrics, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. Tel.: +32 16343856, +32 16343831; fax: +32 16343842.

E-mail address: christiane.deboeck@uzleuven.be (K. De Boeck).

Contents

1.	Introduction	124
2.	Methods	125
3.	Results	125
3.1.	Use of LCI in clinical trials in CF	125
3.2.	Clinimetric properties of LCI	129
3.2.1.	Reliability (Table E2 online)	129
3.2.2.	Validity (Table 2)	129
3.2.3.	Correlation with other outcomes (Table 3)	129
3.2.4.	Predictive validity (Table E3)	129
3.2.5.	Responsiveness (Table 4)	129
3.2.6.	Reference values (Table 5)	133
3.2.7.	Feasibility of LCI (Table E4)	133
3.3.	Group consensus on feasibility	133
3.4.	The “four key questions”	133
3.4.1.	Question 1: Does LCI have the potential to become a surrogate outcome parameter?	133
3.4.2.	Question 2: For what kind of therapeutic trial is LCI appropriate? (therapeutic aim; phase of trial, target population, number of patients involved, number of sites involved)	136
3.4.3.	Question 3: Within what timeline can change be expected and what treatment effect can be considered clinically significant?	136
3.4.4.	Question 4: What studies are needed to further define LCI in CF patients and its potential as a surrogate marker?	136
4.	Conclusion	136
	Acknowledgements	136
	Appendix A. Supplemenatry data	136
	References	136

1. Introduction

In the cystic fibrosis (CF) community, there is a need to focus on developing and evaluating endpoints for clinical trials in early disease. The European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN) has established a Standardisation Committee consisting of researchers with expertise in specific outcome measures. The Standardisation Committee is undertaking a rigorous evaluation of potential outcome measures for multicentre clinical trials in CF. This article summarises the group's work on lung clearance index (LCI).

A full description of the classification of outcome measures is provided in the first document in the series of articles from the

ECFS-CTN Standardisation Committee (CFTR biomarkers group) [1]. Briefly, outcome measures fall into three classes: clinical endpoints, surrogate endpoints and biomarkers. Clinical endpoints reflect how a patient feels, functions or survives and detect a tangible benefit for the patient [2,3]. A surrogate endpoint is a laboratory measurement used to predict the efficacy of therapy when direct measurement of clinical effect is not feasible or practical. Ideally, surrogate endpoints should shorten the period of follow-up required. The link between the surrogate endpoint and long-term prognosis must be proven. Forced expiratory volume in one second (FEV₁) is still the only accepted surrogate outcome for the European Medicines Agency (EMA) and the North American Food and Drug Association (FDA). A biomarker is defined as “a

Table 1
Definitions and justification for clinimetric properties.

Clinimetric property	Definition	Justification of importance
Reliability	Degree to which a measurement is consistent and free from error	Important to quantify error (systematic and random) so that true changes can be discerned from changes due to normal fluctuations
Validity	Concurrent validity: Degree to which a test correlates with a “gold standard” criterion test which has been established as a valid test of the attribute of interest Convergent validity: Degree to which a test correlates with another test which measures the same attribute Discriminate validity: Degree to which a test differentiates between groups of individuals known to differ in the attribute of interest Predictive validity: Degree to which an attribute can be predicted using the result of a predictor test/or degree to which prognosis can be predicted	The gold standard outcome measures are often not feasible. Therefore it is important to know how an alternative outcome measure compares to the gold standard, and how different outcome measures compare. It is important to know the ability of outcome measures to discriminate between different groups
Responsiveness	Degree to which a test changes in response to an intervention known to alter the attribute of interest	Important attribute of tests used in clinical practice or research to assess treatment benefit (e.g. to identify improvements response to an intervention)

characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes or pharmacologic response to a therapeutic intervention". Biomarkers are mainly used to explore proof-of-concept for a specific compound. Some are currently being considered for "promotion" to the status of surrogate endpoint.

Progression of lung disease in CF has slowed down [4], and therefore FEV₁ has become a less sensitive outcome measure. LCI has repeatedly been shown to be superior to FEV₁ to monitor early CF lung disease when FEV₁ is within normal ranges [5,6]. It thus appears a good candidate to become a new surrogate outcome measure in trials focusing on the early stages of disease. LCI may also be useful clinically to monitor patients with FEV₁ within normal ranges, however this article focuses on the use of LCI in clinical trials.

To gain acceptance of researchers and licensing bodies, an endpoint must however have a body of supporting evidence including acceptable clinimetric properties (Table 1) such as reliability, validity and responsiveness to treatment, and sufficient feasibility and safety. Clinimetric properties and feasibility are population and situation dependent, therefore data cannot readily be extrapolated to the CF population from other disease populations.

The aims of this project were 1) to review the literature on reliability, validity and responsiveness of LCI in patients with cystic fibrosis, 2) to gain consensus of the group on the feasibility of LCI and 3) to gain consensus on answers to key questions regarding the promotion of LCI to surrogate endpoint status.

2. Methods

An exhaustive literature search was conducted in MEDLINE, Allied and Complementary Medicine (AMED) and Embase using the following combination of keywords: ("lung clearance index" or "LCI" or "multiple breath washout" or "MBW" or "ventilation inhomogeneity" or "sulphur hexafluoride" or "SF₆" or "nitrogen washout" or "helium washout" or "inert gas washout") and "cystic fibrosis". The search was limited to full text articles in the English language, with no limits on year of publication. A bibliography search was also conducted of all included articles and relevant reviews published until April 2013.

For clinimetric properties, data were extracted and tabulated for reliability, validity, correlation with other outcome measures, responsiveness and reference values. Definitions are given in Table 1.

To evaluate feasibility, data were extracted and tabulated on the proportion of attempts that were successful and reasons for excluding tests. An expert panel also discussed the following topics and reached consensus on each: risk involved, cost, ease of performance, ease of administration, time to administer, equipment and space needed and applicable age group. Specific advantages and limitations of infant pulmonary function were also discussed.

Narrative answers to 4 key questions were discussed by the expert panel during several face to face meetings

1) Does LCI have the potential to become a surrogate outcome?;

- 2) For what kind of therapeutic trial is LCI appropriate? (therapeutic aim, phase of trial, target population, number of patients involved, number of sites involved);
- 3) Within what timeline can change be expected and what treatment effect can be considered clinically significant?;
- 4) What are the most needed studies to further define LCI in patients with CF and to explore its potential as a surrogate marker? The consensus of the group is presented in the current article.

After preparatory work over a period of 6 months, participants with expertise in multiple breath washout met to discuss and develop consensus on the four key questions and feasibility (November 17 and 18, 2010, and June 9, 2011). The manuscript was developed which reports both the systematic review of clinimetric properties (performed by the core writing team (LK, KDB, IS, PR)) and the expert panel's discussions (four key questions and feasibility). This resulted in a draft manuscript which was circulated to the group for review and revision until group consensus was achieved.

3. Results

3.1. Use of LCI in clinical trials in CF

LCI derived from a multiple breath washout (MBW) provides a global measurement of ventilation inhomogeneity. It reflects abnormalities in ventilation in the respiratory tract compared to normal, including the small airways which are affected early in CF lung disease and where changes are not easily detected with traditional pulmonary function techniques such as spirometry [7]. The ability to identify early airway dysfunction in these "silent years", when FEV₁ is often within normal range, is of great importance for investigating new therapies in infants and young children and in those with mild disease [8]. LCI is beginning to be used as an efficacy endpoint in CF clinical trials. It was the primary outcome in a recent phase 2, multicentre trial of ivacaftor in patients with the G551D mutation and normal lung function [9]. It was used in single centre interventional studies of rhDNase and hypertonic saline in infants and children with CF [10–12]. It is one of the major secondary efficacy measures in the ongoing UK CF Gene Therapy Consortium's large, placebo controlled, multidose trial of non-viral gene therapy (<http://clinicaltrials.gov/NCT01621867>).

LCI is derived from a MBW technique which can be performed either with inhalation of an inert tracer gas such as sulphur hexafluoride (SF₆) or helium, or by using 100% oxygen to wash out resident nitrogen. The latter technique has been available for several decades, takes slightly less time to perform and is gaining increasing attention [13]. In the case of an exogenous tracer, the gas is inspired until equilibrium is reached (i.e. concentration of tracer is equal in both inhaled and exhaled air). At this point the tracer gas source is removed and the individual breathes room air until the concentration of the tracer gas in exhaled air is 1/40th of the equilibrium concentration, an arbitrary concentration based on the lower limits of detection of the early nitrogen analysers. In the case of using nitrogen

Table 2
LCI validity.

N and subject type			Apparatus	Gas	Results for LCI	Results for FEV ₁	Statistic	Author
<i>LCI discriminates patients with CF from non-CF subjects</i>								
71	CF	Infants	Mass spectrometer	SF ₆	p = 0.002	p < 0.001*	Unpaired t-test	Hoo [21]
54	Non-CF							
14	CF	Infants	Exhalyzer D ^a	SF ₆	p = 0.022	NR	NA	Belessis [22]
NR	Non-CF							
39	CF	Infants	Mass spectrometer	SF ₆	p < 0.001	p < 0.001*	NR	Lum [23]
21	Non-CF	Infants			0.834 (0.05) N = 22 (56%)	0.836 (0.05)* N = 14 (36%)	Mean (SE) ROC; N (%) individuals with abnormal test	
33	CF	Infants	Mass spectrometer	SF ₆	Sensitivity (39.4%) Specificity (94.3%) AUC _{ROC} = 0.789 (0.68 to 0.90)	NR	Cross tabulation	Haidopoulou [24] (RPN)
35	Non-CF	Infants					AUC _{ROC}	
47	CF	Infants and children	Exhalyzer D ^a	SF ₆	p < 0.001	NR	NA	Belessis [22]
25	Non-CF							
30	Uninfected CF	Infants and children			p < 0.001			
25	Non-CF							
48	CF	Preschool	Mass spectrometer	SF ₆	p < 0.001	p = 0.002	Unpaired t-test	Aurora [35]
45	Non-CF					p < 0.001*		
48	CF	Early school			p < 0.001	p < 0.001		
45	Non-CF					p < 0.001*		
73	CF	Children	Exhalyzer D ^a	N ₂	p < 0.001	NR	Unpaired t-test	Singer [32] (Pediatr Pulmonol)
50	Non-CF							Amin [11]
17	CF	Children	Mass spectrometer	SF ₆	p < 0.001	NR	NR	
28	Non-CF	Children						
45	CF	Children	Mass spectrometer	SF ₆	p < 0.001	NS	MWUT	Keen [40]
35	Non-CF	Children						
22	CF	Children	Mass spectrometer	SF ₆	p < 0.001	p < 0.001	Unpaired t-test	Aurora [30]
33	Non-CF	Children			Sensitivity = 95% Specificity = 97%	Sensitivity = 50% Specificity = 100%	Cross tabulation	
30	CF	Children	Mass spectrometer	SF ₆	p < 0.001	p < 0.05*	Unpaired t-test	Aurora [33] (AJRCCM)
30	Non-CF	Children			Sensitivity = 77%	Sensitivity = 7%*		Owens [25]
56	CF	Children	Mass spectrometer	SF ₆	p < 0.001	p < 0.001	NR	
52	Non-CF	Children						
43	CF	Children (<18 yrs)	Mass spectrometer	SF ₆	p < 0.001	NS	Unpaired t-test	Gustafsson [26] (ERJ)
28	Non-CF							
60	CF	Children	Mass spectrometer	SF ₆	Sensitivity (76.7%) Specificity (96.8%) AUC _{ROC} = 0.94 (0.89 to 0.98)	NR	Cross tabulation	Haidopoulou [24] (RPN)
62	Non-CF	Children					AUC _{ROC}	
5	CF	Children	Modified Innocor ^b	SF ₆	p = NS	NR	Wilcoxon	Pittman [41]
10	Non-CF							
68	CF	Children	EasyOne Pro ^c	SF ₆	p < 0.001	NR	NR	Fuchs [42] (JCF)
38	Non-CF							
18	CF	Children	Modified Innocor ^b	SF ₆	p = 0.022	NS	Unpaired t-test	Horsley [16] (RPN)
29	Non-CF	Children						
15	CF	Children	Exhalyzer D ^a	He	p < 0.001	NR	Unpaired t-test	Bakker [43]
15	Non-CF	Children						

26	CF	Children <18 yrs	Spiroson ^d	SF ₆	p < 0.001	p < 0.01	Unpaired t-test	Fuchs [31]	
22	Non-CF	Children <18 yrs							
10	CF	Children <10 yrs			p = 0.009	NS			
8	Non-CF	Children <10 yrs							
					Specificity = 100% AUC _{ROC} = 0.95 (0.03) p < 0.001 p < 0.001 p < 0.001	Specificity = 100%* AUC _{ROC} = 0.66 (0.07) p < 0.05* NS p < 0.001			
139	CF	Children and adults	EasyOne Pro ^c	SF ₆	p < 0.001	p < 0.001	Unpaired t-tests	Fuchs [20]	
102	Non-CF							(Pediatr Pulmonol)	
11	CF	Children and adults	N ₂ analyser	N ₂	p < 0.01	p < 0.001	ANOVA	Gustafsson [19]	
15	Asthma	Children							
18	Non-CF	Children							
25	CF	Adults	N ₂ analyser	N ₂	p < 0.001	p < 0.001	Unpaired t-test	Verbanck [17]	
25	Non-CF							(ERJ)	
22	CF	Adults	Modified Innocor ^b	SF ₆	p < 0.0001	p < 0.0001	Unpaired t-test	Horsley [16]	
17	Non-CF	Adults						(RPN)	
33	CF	Adults	Modified Innocor ^b	SF ₆	p < 0.001	p < 0.001	MWUT	Horsley [18]	
48	Non-CF	Adults						(Thorax)	
<hr/>									
N and subject type		Apparatus	Gas	Comparison		Results for LCI	Results for FEV1	Statistic	Author
<hr/>									
<i>LCI differs between patients with CF who have different phenotypes</i>									
47	CF	Infants and children	Exhalyzer D ^a	SF ₆	With vs. without <i>P. aeruginosa</i> With vs. without infection	p = 0.038 NS	NA NA	NR	Belessis [22]
27	CF	Infants and children	Exhalyzer D ^a	SF ₆	<i>P. aeruginosa</i> vs. other pathogen	p < 0.01	NA		
49	CF	Infants and children	Exhalyzer D ^a	SF ₆	With vs without bronchiectasis With vs without air trapping	NS NS	NR NR	MWUT	Hall [27]
30	CF	Children	Mass spectrometer	SF ₆	With vs without <i>P. aeruginosa</i>	p < 0.05	NS	Unpaired t-test	Aurora [8]
									(AJRCCM)
22	CF	Children	Mass spectrometer	SF ₆	With vs without <i>P. aeruginosa</i>	p < 0.05	NS	Unpaired t-test	Aurora [30]
43	CF	Children	Mass spectrometer	SF ₆	CF with bacterial colonisation vs. CF	p < 0.01	p < 0.001	Unpaired t-test	Gustafsson
28	Non-CF	(<18 yrs)			without bacterial colonisation				[26]
									(ERJ)
152	CF	Children	Pediatric Pulmonary Unit ^c	N ₂	No infection vs. SA vs. PA vs. SA+PA	p < 0.0001	NR	Linear mixed effect model	Kraemer [44]
18	CF	Children	Modified Innocor ^b	SF ₆	Adults vs. children	p < 0.0001	NR	Unpaired t-test	(Resp Res)
22	CF	Adults							Horsley [16]
									(RPN)
<hr/>									
<i>LCI is a more sensitive indicator of abnormalities than FEV₁</i>									
47	CF	Infants and children	Exhalyzer D ^a	SF ₆	Detection of <i>P. aeruginosa</i>	0.819 (0.686 to 0.951), p = 0.004 Sensitivity = 67% Specificity = 80% PPV = 47% NPV = 93%	NA NA	AUC (95%CI) Sensitivity Specificity (%)	Belessis [22]
49	CF	Infants and children	Exhalyzer D ^a	SF ₆	Extent of bronchiectasis on HRCT	NS	NR	Multivariate regression coefficient	Hall [27]

(continued on next page)

Table 2 (continued)

N and subject type			Apparatus	Gas	Comparison	Results for LCI	Results for FEV ₁	Statistic	Author
<i>LCI is a more sensitive indicator of abnormalities than FEV₁</i>									
43	CF	Children	Mass spectrometer	SF ₆	LCI(+)/FEV ₁ (+) LCI(+)/FEV ₁ (-) LCI(-)/FEV ₁ (-) LCI(-)/FEV ₁ (+)	n = 9 n = 18 n = 15 n = 1	NA	Number subjects (+=abnormal; -= normal)	Gustafsson [26] (ERJ)
28	Non-CF	Children			LCI(+)/FEV ₁ (+) LCI(+)/FEV ₁ (-) LCI(-)/FEV ₁ (-) LCI(-)/FEV ₁ (+)	n = 0 n = 0 n = 28 n = 0			
53	CF	Children	Mass spectrometer	SF ₆	Concordance with abnormal Brody-II HRCT Total concordance with Brody-II HRCT result (both abnormal and normal)	39/53 (74%) 81%	18/57 (32%) 47%	Number (%) subjects	Owens [25]
44	CF	Children and adults	Mass spectrometer	SF ₆	Abnormal when structural abnormalities on HRCT	Bronchiectasis Sensitivity = 85 (71 to 98)% Specificity = 50 (27 to 73)% HRCT Score Sensitivity = 93 (83 to 100)% Specificity = 65 (42 to 87)% Air trapping Sensitivity = 94 (82 to 100)% Specificity = 43 (25 to 61)%	Bronchiectasis Sensitivity = 19 (4 to 34)% Specificity = 89 (74 to 100)% HRCT Score Sensitivity = 26 (9 to 42)% Specificity = 100 (100 to 100)% Air trapping Sensitivity = 25 (4 to 46)% Specificity = 89 (78 to 100)%	Sensitivity and specificity % (95%CI)	Gustafsson [28]
34	CF	Children and adults	EasyOne Pro ^f	SF ₆	Concordance with Bhalla CT Score Abnormal when structural abnormalities on HRCT	28/34 (82.3%) Sensitivity = 88 (69 to 97)% Specificity = 63 (26 to 90)% PPV = 88% NPV = 63%	NA (sample of patients with normal FEV ₁) NA (sample of patients with normal FEV ₁)	Number (%) patients Sensitivity and specificity % (95% CI)	Ellemunter [29]

* = FEV_{0.5}.

aLCI = alveolar lung clearance index, CF = cystic fibrosis, FEV₁ = forced expiratory volume in one second, LCI = lung clearance index, LCI(+) = abnormal LCI, LCI(-) = normal LCI; FEV₁(+) = abnormal FEV₁; FEV₁(-) = normal FEV₁, MES = modified emission spectro-photometer, NA = not applicable, NR = not reported, NS = not significant, SA = *Staphylococcus aureus*, PA = *Pseudomonas aeruginosa*; MS = mass spectrometer; USFS = ultrasonic flow sensor.

^a Exhalyzer D (Ecomedics AG, Duernten, Switzerland).

^b Modified Innocor (Innovision, Odense, Denmark).

^c EasyOne Pro, MBW Module (nidd Medizintechnik AG, Zurich, Switzerland) plus addition of CO₂ analyser (DUET ETCO2 Module, Welch Allyn OEM Technologies, Beaverton, OR, USA).

^d Spiroson (nidd Medical Technologies) plus addition of CO₂ analyser (DUET ETCO2 Module, Welch Allyn OEM Technologies, Beaverton, OR).

^e Pediatric Pulmonary Unit (SensorMedics 220, Yorba Linda, CA, USA).

washout, which is a resident gas, 100% oxygen is delivered until mean expired nitrogen concentration falls below 1/40th of the original concentration. In both methods, LCI is calculated as the cumulative expired volume during the washout phase divided by the functional residual capacity (FRC) i.e. the number of FRC volume turnovers required to clear the tracer gas. FRC is derived from the cumulative exhaled marker gas concentration divided by the difference in end-tidal gas concentration at the start of the washout and the end-tidal concentration at the end of the washout. Individuals with greater ventilation inhomogeneity use a greater number of turnovers to clear the tracer gas and therefore will have a higher (more abnormal) LCI.

Many different systems have been or are being used to measure MBW in clinical trials in CF. For detailed guidelines about washout equipment specifications, test performance and data analysis we refer to a recent ERS/ATS consensus document [14]. Although the mass spectrometer is considered the gold standard gas analyser equipment, it is very expensive, custom built for MBW and therefore not suitable for widespread use [14]. The majority of published results to date are calculated by offline analysis using proprietary software. The use of the software requires training and there is an element of subjectivity in reading the results. For LCI to be used as an outcome measure in large-scale multicentre trials, it is necessary to implement a file transfer and central reading facility. Only with such measures can variability be reduced. Commercially available systems, compliant with the above ERS guidelines will provide the opportunity to standardise the procedure in future multicentre trials. The online Table E1 lists the currently commercially available apparatuses and some of their characteristics. Results from MBW tests using different gases are not interchangeable, e.g. on average, LCI determined by nitrogen washout is higher than LCI determined by washout of SF₆ [15]. Traditionally, the mean of 3 (or at least 2) valid LCI measurements with FRC not differing more than 10% have been reported. The recent ERS document describes acceptability criteria in great detail [14]. If all other criteria are met, the new advice is to only reject tests where FRC differs by >25% from the median values across the 3 tests. Most published studies pre-date this advice and have used a 10% criterion. Throughout the tables we will refer to the apparatus used to obtain the MBW measurements. Since most of the reported studies predate the ERS consensus, all necessary information is not always available.

3.2. Clinimetric properties of LCI

3.2.1. Reliability (Table E2 online)

The majority of studies on reliability were conducted in children, with fewer in infants and adults. In most reports, the mean coefficient of variation (CV) for LCI measurements within one session was low (between 3 and 7%) but the range was higher. A mean CV above 10% was reported in a study in children with CF using an Innocor with a closed circuit. Therefore this apparatus set-up is not recommended [14]. Both CV and ICC of measurements within one session were as acceptable in CF as in healthy controls. One study showed neither a significant nor systematic difference in LCI between

repeated sessions of LCI measurements. A low variability between repeated sessions of LCI measurements has also been reported by others: mean CV of up to 9 % in the short and medium term and high intra-class correlation coefficients.

3.2.2. Validity (Table 2)

Overall, 22 out of 23 studies demonstrated the ability of LCI to discriminate between individuals with CF and healthy, non-CF subjects. Of these, 3 studies included adults only [16–18], the others included either children and adults ($n = 2$) [19,20], or children only ($n = 18$ studies including 4 studies also in infants [21–24]). Several studies demonstrated the ability of LCI to discriminate between groups of patients with CF and differing degrees of lung disease based on age, infection status or structural changes on high resolution computerized tomography (HRCT) of the chest. In this respect LCI is superior to FEV₁. In infants and children, six studies compared the sensitivity of LCI and FEV₁ as indicators of structural lung abnormalities demonstrating that for bronchiectasis and air trapping on HRCT, LCI is more sensitive but less specific than FEV₁ [22,25–29].

3.2.3. Correlation with other outcomes (Table 3)

Twenty one studies have examined the relationship between LCI and other outcome measures with the majority of studies focusing on FEV₁ and HRCT. In 10 studies in children and/or adults with CF, a significant but variable correlation between LCI and FEV₁/FEV_{0.5} was demonstrated [16–18,20,21,29–33]. One study in preschool children reported a correlation with FEV_{0.5}, FEF_{25–75} and sR_{aw}. These studies also pointed out that LCI is superior in detecting abnormalities. In infants with CF diagnosed via newborn screening (mean age 11 weeks) there was no correlation between LCI and FEV_{0.5} [21]. In a mixed group of infants and toddlers (including two with CF), LCI correlated with the volume of trapped gas (expressed as percent of FRC) [34]. Abnormal LCI was shown to have a moderate to strong correlation with structural abnormalities evaluated separately or using global HRCT scores. Overall, correlation was good between LCI and bronchial wall thickening, mucus plugging and bronchiectasis, but weaker with air trapping. LCI was also shown to correlate with other outcome measures including, age, onset of infection, type of infection, inflammation measured in the bronchoalveolar lavage fluid, blood gas analysis, exhaled nitric oxide fraction, capnographic parameters, and symptom score.

3.2.4. Predictive validity (Table E3)

One study demonstrated the validity of LCI in preschool children as a predictive test of abnormal lung function at an early school age. Whilst positive predictive values for future abnormalities were also good for FEV₁, LCI had a stronger negative predictive value [35]. Further studies to investigate the relationship between LCI measurements and the long term course of CF (lung function, exacerbations etc.) are urgently required.

3.2.5. Responsiveness (Table 4)

Several studies provide information on responsiveness of LCI in small numbers of patients (range $n = 11$ to 38). In patients with CF, LCI was able to detect a treatment effect after four weeks of

Table 3

Cross sectional correlation between LCI and other measures.

N and subject type		Apparatus	Gas	Comparison	Result	Statistic	Author
<i>In children and adults with CF, LCI correlates with specific spirometry parameters such as FEV₁ and MEF₂₅</i>							
22	CF	Children	Mass spectrometer	SF ₆ FEV ₁	$r^2 = -0.62, p < 0.0005$	Linear regression	Aurora [30]
1				MEF ₂₅	$r^2 = -0.46, p < 0.001$		
26	CF	Children	Spiroson ^a	SF ₆ FEV ₁	$r = -0.476, p = 0.014$	Spearman correlation coefficient	Fuchs [31]
2				MEF ₂₅	$r = -0.523, p = 0.006$		
139	CF	Children and adults	EasyOne Pro ^b	SF ₆ FEV ₁ z-score	$p < 0.001$	NR	Fuchs [20] (Pediater Pulmonol)
3				MEF ₂₅	$p < 0.001$		
34	CF	Children and adults	EasyOne Pro ^b	SF ₆ FEV ₁	$r = 0.468, p = 0.005$	Pearson correlation coefficient	Ellemunter [29]
4							
33	CF	Adults	Modified Innocor ^c	SF ₆ FEV ₁	$r^2 = 0.69, p < 0.001$	Linear regression	Horsley [18] (Thorax)
5							
40	CF	Adults and children	Modified Innocor ^c	SF ₆ FEV ₁ z-score	$r = -0.86, p < 0.0001$	Spearman correlation coefficient	Horsley [16] (RPN)
6				Curvilinearity of washout tracing	$r = -0.88, p < 0.0001$		
22	CF	Adults		RV/TLC	$r = 0.73, p < 0.0002$		
25	CF	Adults	N ₂ analyser	N ₂ FEV ₁	$r = -0.76, p < 0.001$	Spearman correlation coefficient	Verbanck [17] (ERJ)
7							
73	CF	Children	Exhalyzer D ^e	N ₂ FEV ₁ z-score	$r = -0.49, p < 0.001$	Pearson correlation coefficient	Singer [32] (Pediater Pulmonol)
				FEV ₁ /FVC z-score	$R = -0.44, p = 0.003$		
				FEF _{25–75} z-score	$R = -0.51, p < 0.001$		
<i>In preschool children with CF, LCI correlates with FEV_{0.5}, FEF_{25–75} and sR_{aw}</i>							
30	CF	Children	Mass spectrometer	SF ₆ sR _{aw}	$r^2 = -0.14, p = 0.04$	Linear regression	Aurora [8] (AJRCCM)
		2–5 yrs		FEV _{0.5}	$r^2 = 0.21, p = 0.01$		
				FEF _{25–75}	$r^2 = 0.28, p = 0.003$		
<i>In infants with CF detected after newborn screening, LCI did not correlate with FEV_{0.5}</i>							
71	CF	Infants after NBS	Mass spectrometer	SF ₆ FEV _{0.5}	NS	Pearson correlation coefficient	Hoo [21]
		Mean age 11 wks					
<i>In a mixed group of infants and toddlers (including 2CF), LCI correlated with the proportion of trapped gas</i>							
8	3 risk of atopy 3 ex-premie 2 CF With and without respiratory disease	Children	Mass spectrometer	SF ₆ V _{TG, SF6} /FRC	$r^2 = 0.94, p < 0.001$	Linear regression	Gustafsson [26] (Pediater Pulmonol 35:42–49)
<i>LCI correlates well with parameters derived from imaging analysis.</i>							
49	CF	Infants and children	Exhalyzer D ^e	SF ₆ Extent of bronchiectasis on HRCT	NS	Spearman correlation coefficient	Hall [27]
				Extent of air trapping on HRCT	$r = 0.31, p = 0.03$		
57	CF	Children	Mass spectrometer	SF ₆ Brody-II HRCT total score	$r = 0.77$	Spearman correlation coefficient	Owens [25]
				Brody-II bronchiectasis score	$r = 0.71$		
				Brody-II peribronchial thickening score	$r = 0.72$		
				Brody-II mucous plugging score	$r = 0.67$		
				Brody-II air trapping score	$r = 0.58$		
34	CF	Children and adults	EasyOne Pro ^b	SF ₆ Bhalla HRCT score	$r = -0.54, p = 0.001$	Pearson correlation coefficient	Ellemunter [29]

44	CF	Children and adults	Mass spectrometer	HRCT scores	$r = 0.65$ to 0.85	Spearman correlation coefficient	Gustafsson [28]
26	CF	Children	Spiroson ^a	SF ₆ Crispin-Norman X-ray score	$r = 0.684$, $p = 0.001$ No sig. correlation between CN score and FEV ₁ *	Spearman correlation coefficient	Fuchs [31]
<i>LCI correlates with some other parameters of disease severity</i>							
71	CF	Infants	Mass spectrometer	SF ₆ Homozygous F508del Respiratory symptoms Positive growth (cough swab) Antibiotics	NS NS NS NS	Linear regression	Hoo [21]
47	CF	Infants and children	Exhalyzer D ^c	SF ₆ LCI vs. pathogen load (CFU/mL) LCI vs. IL-8 LCI vs. neutrophil count	$R^2 = 0.10$, $p = 0.031$ $R^2 = 0.20$, $p = 0.004$ $R^2 = 0.21$, $p = 0.001$	Linear regression	Belessis [22]
73	CF	Children	Exhalyzer D ^c	N ₂ <i>P. aeruginosa</i> infection status PaO ₂	$r = 0.75$, $p < 0.001$ $r = -0.54$	Pearson correlation coefficient	Singer [32] (Pediatr Pulmonol)
142	CF	Children	Pediatric Pulmonary Unit ^f	N ₂ Age Age at onset of chronic <i>PA</i> infection CFTR genotype	$F = 22$, $p < 0.0001$ $F = 4.2$, $p = 0.02$ NS	Linear mixed effect model	Kraemer [45]
178	CF	Children	Pediatric Pulmonary Unit ^f	N ₂ PaO ₂ <80 mm Hg	t -Statistic = -3.156 , $p = 0.002$	Linear mixed model, adjusted by year at testing	Kraemer [46] (Respiratory Research)
15	CF	Children	Exhalyzer D ^c	He PaO ₂ above or below 80 mm Hg LCI vs. Mean nocturnal oxygen saturations	$\chi^2 = 9.644$, $p = 0.002$ NS	Chi square Spearman correlation coefficient	Bakker [43]
15	Non-CF	Children		LCI vs. Mean cough (cough s/h) LCI vs. mean nocturnal oxygen saturations LCI vs. Mean cough (cough s/h)	NS NS NS		
68	CF	Children and adults	EasyOne Pro ^b	SF ₆ Slope 2 of CO ₂ expirogram Slope 3 of CO ₂ expirogram Capnographic index (KPI _v)	$r = -0.198$, $p < 0.042$ $r = 0.376$, $p < 0.001$ $r = 0.610$, $p < 0.001$	Pearson correlation coefficient	Fuchs [42] (JCF)
45	CF	Children	Mass spectrometer	SF ₆ FENO ₅₀ Alveolar NO FENO ₅₀	$r = -0.43$, $p = 0.003$ $r = -0.32$, $p = 0.037$ $\beta = -0.251$ 95%CI: -0.354 to -0.147 , $p < 0.001$	Spearman correlation coefficient Multiple regression model (dependent variable: log FENO ₅₀)	Keen [40]
28	CF	Children	V _{max} 22D ^d	N ₂ Change in CFCS in response to IVAB	$r = 0.48$, $p = 0.01$	NR	Robinson [36] (Pediatr Pulmonol)

CFU = colony forming units; FEF_{25–75} = mean forced expiratory flow between 25 and 75% of exhaled vital capacity; FENO₅₀ = fractional exhaled nitric oxide, measured at a flow rate of 50 ml/s; FEV_x = forced expiratory volume in x seconds; HRCT = high resolution computed tomography; IVAB = intravenous antibiotics; MEF₂₅ = forced expiratory flow where 25% of the FVC remains to be expired; NS = not significant; USFS = ultrasonic flow sensor; NR = not reported; RV/TLC = ratio of residual volume to total lung capacity; sR_{aw} = specific airway resistance measured by body plethysmography; V_{TG, SF6/FRC} = volume of trapped gas as measured with sulphur hexafluoride as tracer gas.

^a Spiroson (ndd Medical Technologies) plus addition of CO₂ analyser (DUET ETCO₂ Module, Welch Allyn OEM Technologies, Beaverton, OR, USA).

^b EasyOne Pro, MBW Module (ndd Medizintechnik AG, Zurich, Switzerland) plus addition of CO₂ analyser (DUET ETCO₂ Module, Welch Allyn OEM Technologies, Beaverton, OR, USA).

^c Modified Innocor (Innovision, Odense, Denmark).

^d Vmax 22D spirometer and Spectra software (SensorMedics Corp., Yorba Linda, CA, USA).

^e Exhalyzer D (Ecomedics AG, Duernten, Switzerland).

^f Pediatric Pulmonary Unit (SensorMedics 220, Yorba Linda, CA, USA).

Table 4
Responsiveness of LCI in cystic fibrosis.

N	Subject type	Apparatus	Gas	Intervention	LCI results (mean SD)	Did other endpoints detect difference?	Statistic	Author
<i>LCI decreases after 2 weeks treatment with IV antibiotics, and after 4 weeks treatment with hypertonic saline and rhDNase in patients with cystic fibrosis</i>								
16	Children	Easyone Pro ^a	SF ₆	Endurance training and flutter/PEP	p = NS pre-ACT: 7.76 (1.23), post-ACT: 7.96 (1.04)	NS	Paired t	Fuchs [47] (Pediater Pulmonol)
11	Children and adults	MES ^b	N ₂	Salbutamol, 5 mg once	p = NS	S _{acin} p < 0.01 FEV ₁ p < 0.01	Paired t	Gustafsson [19]
20	Children	Mass spectrometer	SF ₆	7% hypertonic saline, 4 ml BID 4 wk vs. Isotonic saline, 4 ml BID 4 wk	p = 0.016 Rx effect: 1.16 (0.94), 95% CI [0.27 to 2.05] HTS: pre: 8.84 (1.95), post: 7.86 (1.71) ITS: pre: 8.71 (2.10), post: 8.89 (2.10)	No (spirometry NS)	Repeated measures ANOVA	Amin [10]
17	Children	Mass spectrometer	SF ₆	rhDNase, 2.5 ml QD 4 wk vs. Placebo, 2.5 ml QD 4 wk	p = 0.02 Rx effect: −0.90 (1.44) rhDNase: pre: 8.31 (1.48), post: 7.69 (1.65) Placebo: pre: 8.75 (1.72), post: 8.52 (1.19)	FEF _{25–75} %pred p = 0.03 FEF _{25–75} z-score p = 0.03	Mixed model	Amin [11]
28	Children	V _{max} 22D ^c	N ₂	IV antibiotics	p = 0.03 Rx effect: 3.8% decrease Admission: 10.10 range [6.87 to 14.83] Discharge: 9.62 range [7.37 to 13.45]	CFCS p < 0.01 FEV ₁ p < 0.01 FVC p < 0.01 RV/TLC p < 0.05 VO _{2peak} p < 0.05	Paired t-test	Robinson [7]
38	Adults	Innocor ^d	SF ₆	IV antibiotics	p = 0.003 Rx effect: −0.8 (1.4) Start IVAB: 14.6 (2.7) End IVAB: 13.8 (2.4)	Yes ^e	Paired t-test	Horsley [37]

Abbreviations: CFCS = cystic fibrosis clinical score, FEV₁ = forced expiratory volume in 1 s, FVC = forced vital capacity, IQR = interquartile range, MES = modified emission spectrophotometer, NS = not significant; RV/TLC = residual volume to total lung capacity ratio, S_{acin} and S_{cond} additional LCI parameters (for more info see review, Robinson [7]), wk = weeks.

^a EasyOne Pro, MBW Module (nidd Medizintechnik AG, Zurich, Switzerland) plus addition of CO₂ analyser (DUET ET/CO₂ Module, Welch Allyn OEM Technologies, Beaverton, OR, USA).

^b Medscience 505 (Medscience Electronics, Inc., St. Louis, MO, USA).

^c V_{max} 22D spirometer and Spectra software (SensorMedics Corp., Yorba Linda, CA, USA).

^d Modified Innocor (Innovision, Odense, Denmark).

^e Large number of endpoints explored: in general clinical observations, symptom scores, lung function, serum inflammatory markers and some structural endpoints improved.

inhalation of dornase alpha [10], four weeks of inhalation of hypertonic saline [11] and after a course of intravenous antibiotics for a respiratory exacerbation [10,11,36,37]. One short term study did not show a statistically significant treatment effect with 5 mg of inhaled salbutamol as measured by LCI in 11 children and adults with CF. Only S_{acin} improved, an index derived from MBW which reflects inhomogeneity in the airways close to or within the gas exchange zone [19]. It may not be surprising that LCI did not detect change; bronchodilators target larger airways whereas LCI is considered to be more reflective of ventilation homogeneity in smaller airways. There is also little information on the efficacy of inhaled bronchodilator therapy in CF using other outcome measures.

3.2.6. Reference values (Table 5)

Reported reference values predate the ERS guideline. We list the reported reference ranges according to gas used, set-up used and age category. It is important to note that reference values are dependent on age of participants, method of analysis (i.e. online vs. offline), software used, device and set-up and tracer gas used. Reference values are not interchangeable between different methods. In addition, we refer to an abstract containing reference values for commercially available equipment over a wide age range [38].

3.2.7. Feasibility of LCI (Table E4)

Feasibility data were collated from studies in CF, and are mainly from children; fewer studies have been conducted in adults or infants. In children, success rates ranged from 24% to 100%. The study with the lowest success rates was evaluating feasibility in the clinical setting in which strict time constraints were imposed (20 min for participant familiarisation and performance of measurement). This is not as relevant in clinical trials as there tends to be more time for participant familiarisation and performance of repeat measures [32]. In infants and preschool children, success rate can be lower. Common reasons for exclusion of tests include manoeuvres that are not technically acceptable (e.g. unstable breathing pattern) or lack of within-session reproducibility (i.e. no two curves within 10% for FRC measurement). The experience of several hundred LCI measurements in adults with CF in the UK CF Gene Therapy Consortium gene therapy studies indicates feasibility in this group of close to 100% (unpublished observations).

3.3. Group consensus on feasibility

MBW is a safe technique since it uses either oxygen for nitrogen washout or very low concentrations of inert tracer gases SF_6 and helium.

For young children, quiet breathing is performed using a face mask, whereas for older children and adults, a mouth piece is used. In neonates the test can be attempted during natural sleep. This is usually impossible beyond the neonatal period.

Few have embarked on LCI measurements in children under the age of three years, especially beyond the newborn period. From experience with other lung function tests, it is anticipated that the test duration and the need for regular and quiet breathing

will imply sedation. As for any test done under sedation this requires close monitoring and is associated with a small risk. In infants with rapid breathing rates, the gas analyser must have a rapid response time. Commercial stand alone SF_6 analysers can be adapted to provide the rapid response times necessary to measure LCI in infants. Most studies in infants have used a mass spectrometer. The nitrogen washout technique has not yet been validated in infants in whom the impact of breathing 100% oxygen on ventilation pattern should be further explored.

In infants and preschoolers, MBW is simpler than forced expiratory techniques. MBW requires only quiet tidal breathing whereas the raised volume rapid thoraco-abdominal compression (RVRTC) technique requires high skill, long term and continuous training and numerous acceptability criteria. RVRTC feasibility in infants has a much lower feasibility than LCI when comparing the percent of successful measurements (albeit between studies). A large multicentre trial evaluating feasibility in RVRTC also showed that feasibility was much lower in naive centres compared to more experienced ones, demonstrating the dependence on training and experience [67].

MBW takes more time than routine spirometry. In general, three repeat measurements are performed to generate a single mean value. In healthy subjects, both phases take approximately less than 5 min. Both wash-in and wash-out require less time in healthy subjects than in people with obstructive airways disease. The time needed increases relative to the increase of LCI. The nitrogen wash-out technique has the advantage of being shorter, as a wash-in is not needed before the 1st washout. The time the patient is attached to the equipment is also reduced since all wash-in phases are done with room air. Time requirements also increase when off-line analysis is used, however automated calculation of LCI from the MBW tracer helps to reduce analysis time. The manpower required increases when testing infants and young children, as at least two people are needed.

The equipment (hardware and software) and consumables required depend on the technique used [14]. In general the following should be considered; a trolley-mounted analyser or mass spectrometer, space for the tracer gas cylinder, a seat for the individual, a TV/DVD for distraction and a computer with software for data storage and analysis. These can easily be accommodated in most lung function laboratories. Tracer gas build-up in confined spaces should be prevented by good ventilation of the test room. In multicentre studies, the tracer gas used must be approved by all national authorities, which may limit the use of SF_6 .

Ongoing developments may further improve LCI feasibility; assessing whether results from partial washout (first breaths) predict the 'standard' LCI value. The additional value of other indices derived from MBW, such as S_{acin} and S_{cond} , that describe the site of ventilation inhomogeneity, are being explored.

3.4. The "four key questions"

3.4.1. Question 1: Does LCI have the potential to become a surrogate outcome parameter?

LCI is potentially very valuable as a surrogate outcome parameter. It reflects disease in the peripheral airways which

Table 5
Reference values for LCI in healthy controls according to inert gas, age and apparatus used.

N	Age group	Additional info	Apparatus	Mean LCI Median*	SD SE*	Range IQR*	95% CI	Upper limit of normality	Author
<i>SF₆</i>									
201	Infants		Exhalyzer D ^a	6.6*	NR	5.5 to 8.6	NR	NR	Kieninger [48]
29	Infants	Preterm	Exhalyzer D ^a	7.3	NR	6.0 to 10.3	NR	NR	Sinhal [49]
29	Infants	Time 1 Preterm Time 2	Exhalyzer D ^a	7.5	NR	6.3 to 10.6	NR	NR	Sinhal [49]
64	Infants	Full term	Exhalyzer D ^a	7.17	0.54	NR	NR	NR	Hülkamp [50]
59	Infants	Preterm	Exhalyzer D ^a	7.14	0.88	NR	NR	NR	Hülkamp [50]
16	Infants	Full term	Exhalyzer D ^a	6.51	0.27	NR	NR	NR	Riedel [51]
14	Infants	Preterm	Exhalyzer D ^a	6.54	0.49	NR	NR	NR	Riedel [51]
20	Infants	Facemask	Exhalyzer D ^a	6.6	0.8	NR	NR	NR	Schulzke [52]
20	Infants	Nosemask	Exhalyzer D ^a	7.2	0.9	NR	NR	NR	Schulzke [52]
25	Infants and children		Exhalyzer D ^a	6.45	0.49	5.42 to 7.37		7.41	Belessis [22]
39	Children		Exhalyzer D ^a	5.5*	NR	4.2 to 6.8	NR	NR	Kieninger [48]
185	Infants	Full term	Spiroson ^b	7.0	0.8	5.5 to 10.1	NR	NR	Latzin [53]
239	Infants	Preterm	Spiroson ^b	6.9	0.7	5.2 to 8.5	NR	NR	Latzin [53]
22	Children		Spiroson ^b	6.7	0.5	5.8 to 7.6	NR	7.77	Fuchs [31]
9	Adults		Spiroson ^b	7.10	0.30	NR	NR	NR	Fuchs [54]
10	Adults	Supine	Spiroson ^b	5.63	0.43	NR	NR	NR	Riedel [55]
10	Adults	Prone	Spiroson ^b	7.13	0.64	NR	NR	NR	Riedel [55]
10	Adults	Left lateral lying	Spiroson ^b	6.27	0.44	NR	NR	NR	Riedel [55]
10	Adults	Right lateral lying	Spiroson ^b	6.65	0.52	NR	NR	NR	Riedel [55]
22	Children (<18y)	Hannover	EasyOne Pro ^c	6.13	0.3	5.57 to 6.64	NR	7.0	Fuchs [56]
22	Children (<18y)	Innsbruck	EasyOne Pro ^c	6.27	0.5	5.36 to 7.06			
102	Children and adults		EasyOne Pro ^c	6.3	0.19	NR	NR	NR	Fuchs [20] (Pediatr Pulmonol)
10	Children		Modified Innocor ^d	5.98	1.22	3.74 to 7.53	NR	NR	Pittman [41]
29	Children		Modified Innocor ^d	6.24	0.47	5.14 to 7.05	NR	NR	Macleod [57]
12	Children		Modified Innocor ^d	6.3	0.5	5.6 to 7.1	NR	7.3	Horsley [18]
29	Children		Modified Innocor ^d	6.2	0.5	5.1 to 7.1	NR	7.5*	(Thorax) Horsley [16] (RPN)
48	Adults		Modified Innocor ^d	6.7	0.4	6.0 to 7.8	NR	7.5	Horsley [18] (Thorax)
17	Adults		Modified Innocor ^d	6.7	0.6	5.9 to 7.9	NR	7.5*	Horsley [16] (RPN) <i>ULN calculated from combined sample of adults and children*</i>
21	Infants		Mass spectrometer	7.2	0.3	NR	NR	7.8	Lum [23]
45	Preschool		Mass spectrometer	6.69	0.5	NR	NR		Aurora [35]
45	Early school		Mass spectrometer	6.67	0.5	NR	NR		Aurora [35]
28	Children		Mass spectrometer	6.13	0.41	NR	NR	6.95	Amin [11]
72	Children		Mass spectrometer	6.6*	NR	6.5 to 6.7*	NR	NR	Sonnappa [58]
35	Children		Mass spectrometer	5.9*	NR	5.1 to 7.8	NR	NR	Keen [40]

31	Children		Mass spectrometer	6.89	0.44	NR		7.77	Aurora [8] (AJRCCM)
33	Children		Mass spectrometer	6.45	0.49	NR	NR	7.41	Aurora [40]
28	Children (<18 yrs)		Mass spectrometer	6.33	0.43	NR	NR	7.17	Gustafsson [26] (ERJ)
52	Children		Mass spectrometer	6.6	0.5	NR	NR	7.5	Owens [25]
9	Adults		Mass spectrometer	7.21	0.26	NR	NR	NR	Fuchs [54]
11	Adults	Standing, V _T of 750 ml	Mass spectrometer	7.10	0.17*	NR	NR	NR	Grönkvist [59]
11	Adults	Standing, V _T of 1000 ml	Mass spectrometer	7.05	0.15*	NR	NR	NR	Grönkvist [59]
11	Adults	Standing, V _T of 1250 ml	Mass spectrometer	7.05	0.17*	NR	NR	NR	Grönkvist [59]
11	Adults	Supine, V _T of 750 ml	Mass spectrometer	6.95	0.16*	NR	NR	NR	Grönkvist [59]
11	Adults	Supine, V _T of 1000 ml	Mass spectrometer	7.07	0.16*	NR	NR	NR	Grönkvist [59]
11	Adults	Supine, V _T of 1250 ml	Mass spectrometer	7.23	0.18*	NR	NR	NR	Grönkvist [59]
N	Age group	Additional info	Apparatus	Mean LCI Median*	SD SE*	Range IQR*	95% CI	Limits of normality	Author
<i>N₂</i>									
50	Children	Healthy	Exhalyzer D ^a	6.1	0.9	NR	NR	7.9	Singer [32]
20	Pre-term infants	Healthy	N ₂ analyser	10.8	1.4	NR	NR	NR	Shao [60]
32	Infants	Preterm	N ₂ analyser	11.3	2.05	NR	NR	NR	Hjalmarson [61]
53	Infants	Full-term	N ₂ analyser	10.2	1.82	NR	NR	NR	Hjalmarson [61]
60	Adults	Female	N ₂ analyser	6.26	0.44	NR	NR	NR	Verbanck [62]
60	Adults	Male	N ₂ analyser	6.28	0.39	NR	NR	NR	Verbanck [62]
30	Adults	Female	N ₂ analyser	5.77	0.50	NR	NR	NR	Verbanck [62]
30	Adults	Male	N ₂ analyser	5.65	0.49	NR	NR	NR	Verbanck [62]
17	Adults		N ₂ analyser	7.02	0.6	NR	NR	NR	Downie [63]
10	Adult	Female	N ₂ analyser	7.6	1.0	NR	NR	NR	Arborelius [64]
11	Adult	Male	N ₂ analyser	7.5	0.9	NR	NR	NR	Arborelius [64]
12	Children	Sitting	MES ^c	6.39	0.36	NR	NR	NR	Gustafsson [26] (Pediatr Pulmonol 36:34–42)
12	Children	Supine (0 min)	MES ^c	6.31	0.56	NR	NR	NR	Gustafsson [26] (Pediatr Pulmonol 36:34–42)
12	Children	Supine (30 min)	MES ^c	6.29	0.47	NR	NR	NR	Gustafsson [26] (Pediatr Pulmonol 36:34–42)
12	Children	Supine (60 min)	MES ^c	6.39	0.43	NR	NR	NR	Gustafsson [26] (Pediatr Pulmonol 36:34–42)
<i>He</i>									
28	Infants (3 to 28 mo)	Full term	Mass spectrometer	9.3	NR	NR	9.1 to 9.6	NR	Chakr [65]
18	Children		Mass spectrometer	6.50	0.45	NR	NR	NR	Aljassim [66]
18	Children		Mass spectrometer	6.54	0.47	NR	NR	NR	Aljassim [66]

MES = modified emission spectrophotometer, NR = not reported, V_T = tidal volume. * signifies median or IQR.

^a Exhalyzer D (Ecomedics AG, Duernten, Switzerland).

^b Spiroson(R), Ecomedics AG, Duernten, Switzerland.

^c EasyOne Pro, MBW Module (nidd Medizintechnik AG, Zurich, Switzerland) plus addition of CO₂ analyser (DUET ETCO₂ Module, Welch Allyn OEM Technologies, Beaverton, OR, USA).

^d Modified Innocor (Innovision, Odense, Denmark).

^e Medscience 505 (Medscience Electronics, Inc., St. Louis, MO, USA).

occurs early in CF lung disease and is not detected with traditional spirometric measures such as FEV₁. LCI has a significant and growing evidence base which indicates that its clinimetric properties are positive and more useful than traditional spirometric parameters in early or mild disease. LCI has a well-established and acceptable safety and feasibility profile throughout the spectrum of ages and severities of CF lung disease. The test performance has been standardised in a recent ERS/ATS guideline [14]. The use of LCI in multicentre clinical trials will be facilitated in the near future by the standardisation efforts such as those by the ECFS-CTN Standardisation Committee: agreed standard operating procedures for performance of the measurement and for training and certification procedures, central quality control and the availability of central over-reading. The availability of commercial systems and systems that do not require specific gases such as SF₆ may also boost more general use and facilitate standardisation between centres in large scale trials.

3.4.2. Question 2: For what kind of therapeutic trial is LCI appropriate? (therapeutic aim; phase of trial, target population, number of patients involved, number of sites involved)

At present LCI has mainly been used in phase two trials evaluating therapeutic benefit. A recent phase two trial of ivacaftor in patients with mild lung disease showed that LCI was more responsive to treatment than FEV₁ [9]. A post-hoc power analysis demonstrated a much lower number of patients needed when using LCI rather than FEV₁ as primary outcome. Since this was a multicentre trial, it also demonstrates the feasibility of using LCI across centres in different countries. The accumulating evidence indicates that, in addition to phase two trials, LCI is becoming applicable to phase three trials. Given LCI's greater sensitivity than FEV₁, it is especially appropriate for use in phase three trials in small populations (e.g. rare mutations), young children, patients with mild lung disease, or to reduce the number of subjects needed.

3.4.3. Question 3: Within what timeline can change be expected and what treatment effect can be considered clinically significant?

Available studies have not addressed how quickly LCI changes after an intervention. The biological mechanisms underlying abnormally raised LCI are thought to be (a) regional airway endoluminal obstruction by retained secretions, (b) regional airway obstruction due to mucosal airway inflammation and (c) regional remodelling/fibrosis/destruction of airways. Mechanisms (a) and (b) are amenable to change over days and improvements in LCI following treatment of acute CF exacerbations have been documented. A raised LCI might also have an irreversible part related to structural abnormalities (c).

The treatment effect that can be considered clinically significant should be larger than the difference in LCI seen between repeat measurements without intervention or change in clinical status. In healthy children and using SF₆ as inert gas and mass spectrometer as analyser, the CoR was 0.74 or 11% of the baseline value [39]. When using nitrogen washout and a commercial set-up, CoR was 0.6 in healthy children and 0.96 in children with CF [32]. For more data on test repeatability we refer to Table E2.

3.4.4. Question 4: What studies are needed to further define LCI in CF patients and its potential as a surrogate marker?

1. Clinical relevance: variability of LCI in preschool children and infants. Correlation of LCI with clinical outcome parameters such as time to pulmonary exacerbation. Use of LCI in a multicentre setting to study treatment benefit in preschool children and infants. Longitudinal evolution from birth in a large cohort of CF patients.
2. Methodology: further comparisons of LCI measured according to the recent consensus but using the different possible set-ups; normative ranges and CoR across ages and for all techniques.
3. Additional information compared to other outcome parameters: correlation with regional ventilation abnormalities as defined by imaging (e.g. hyperpolarized helium). Ideally these studies should be interventional (e.g. before and after treatment). Further correlations with inflammatory markers in bronchoalveolar lavage or/and sera.

4. Conclusion

This document provides an overview of the work of the ECFS-CTN Standardisation Committee on LCI. A systematic review of the clinimetric properties of LCI demonstrates its reliability, validity and responsiveness. LCI also has an attractive feasibility profile. It is particularly useful for multicentre trials in young children with CF and in patients with early or mild CF lung disease when FEV₁ is within normal range. This is the first article to collate the literature on LCI and CF in this manner and provides a strong evidence base to support the use of LCI in clinical trials in CF.

Acknowledgements

We wish to acknowledge the support of the NIHR Respiratory Biomedical Research Unit at the Royal Brompton NHS Foundation Trust and Imperial College London.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.jcf.2013.09.005>.

References

- [1] De Boeck K, Kent L, Davies J, Derichs N, Amaral M, Rowe S, et al. CFTR biomarkers: time for promotion to surrogate endpoint? *Eur Respir J* 2013;41(1):203–16.
- [2] De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, et al. Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. *Control Clin Trials* 2001;22(5):485–502.
- [3] Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther* 2001;69(3):89–95.
- [4] Liou TG, Elkin EP, Pasta DJ, Jacobs JR, Konstan MW, Morgan WJ, et al. Year-to-year changes in lung function in individuals with cystic fibrosis. *J Cyst Fibros* 2010;9(2):250–6.
- [5] Fuchs SI, Gappa M. Lung clearance index: clinical and research applications in children. *Paediatr Respir Rev* 2011;12(4):264–70.

- [6] Stocks J, Thia LP, Sonnappa S. Evaluation and use of childhood lung function tests in cystic fibrosis. *Curr Opin Pulm Med* 2012;18(6):602–8.
- [7] Robinson PD, Goldman MD, Gustafsson PM. Inert gas washout: theoretical background and clinical utility in respiratory disease. *Respiration* 2009;78:339–55.
- [8] Aurora P, Kozłowska W, Stocks J. Gas mixing efficiency from birth to adulthood measured by multiple-breath washout. *Respir Physiol Neurobiol* 2005;148:125–39.
- [9] Davies JC, Sheridan H, Lee P-S, Song T, Stone A, Ratjen F. Effect of ivacaftor on lung function in subjects with CF who have the G551D-CFTR mutation and mild lung disease: a comparison of lung clearance index (LCI) vs. spirometry. *J Cyst Fibros* 2012;11(Suppl. 1):S15.
- [10] Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. *Thorax* 2010;65:379–83.
- [11] Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, et al. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. *Eur Respir J* 2011;37:806–12.
- [12] Subbarao P, Stanojevic S, Brown M, Jensen R, McDonald N, Gent K, et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. *Pediatr Pulmonol* 2012;47(Suppl. 35):223.
- [13] Singer F, Houlitz B, Latzin P, Robinson PD, Gustafsson P. A realistic validation study of a new nitrogen multiple-breath washout system. *PLoS One* 2012;7(4):e36083.
- [14] Robinson P, Latzin P, Verbanck S, Hall GL, Horsley AR, Gappa M, et al. Consensus statement for inert gas washout measurement using multiple and single breath tests. *Eur Respir J* 2013;41(3):507–22.
- [15] Jensen R, Stanojevic S, Gibney K, Salazar JG, Gustafsson PM, Subbarao P, et al. Multiple breath nitrogen washout: a feasible alternative to mass spectrometry. *PLoS One* 2013;8(2):e56868.
- [16] Horsley AR, Macleod KA, Robson AG, Lenney J, Bell NJ, Cunningham S, et al. Effects of cystic fibrosis lung disease on gas mixing indices derived from alveolar slope analysis. *Respir Physiol Neurobiol* 2008;162:197–203.
- [17] Verbanck S, Paiva M, Paeps E, Schuermans D, Malfroot A, Vincken W, et al. Lung clearance index in adult CF patients: the role of convection-dependent lung units. *Eur Respir J* 2013;42(2):380–8. <http://dx.doi.org/10.1183/09031936.00125312>.
- [18] Horsley AR, Gustafsson PM, Macleod KA, Saunders C, Greening AP, Porteous DJ, et al. Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis. *Thorax* 2008;63:135–40.
- [19] Gustafsson PM. Peripheral airway involvement in CF and asthma compared by inert gas washout. *Pediatr Pulmonol* 2007;42:168–76.
- [20] Fuchs SI, Ellemunter H, Eder J, Mellies U, Grosse-Onnebrink J, Tummler B, et al. Feasibility and variability of measuring the lung clearance index in a multi-centre setting. *Pediatr Pulmonol* 2012;47(7):649–57.
- [21] Hoo A, Thia LP, Nguyen TTD, Bush A, Chudleigh J, Lum S, et al. Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening. *Thorax* 2012;67:874–81.
- [22] Belessis Y, Dixon B, Hawkins G, Pereira J, Peat J, MacDonald R, et al. Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index. *Am J Respir Crit Care Med* 2012;185(8):862–73.
- [23] Lum S, Gustafsson PM, Ljungberg H, Hülskamp G, Bush A, Carr S, et al. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests. *Thorax* 2007;62:341–7.
- [24] Haidopoulou K, Lum S, Turcu S, Guinard C, Aurora P, Stocks J, et al. Alveolar LCI vs. standard LCI in detecting early CF lung disease. *Respir Physiol Neurobiol* 2012;180:247–51.
- [25] Owens CM, Aurora P, Stanojevic S, Bush A, Wade A, Oliver C, et al. Lung clearance index and HRCT are complementary markers of lung abnormalities in young children with CF. *Thorax* 2011;66:481–8.
- [26] Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. *Eur Respir J* 2003;22:972–9.
- [27] Hall GL, Logie KM, Parsons F, Schulzke SM, Nolan G, Murray C, et al. Air trapping on chest CT is associated with worse ventilation distribution in infants with cystic fibrosis diagnosed following newborn screening. *PLoS One* 2011;6(8):e23932.
- [28] Gustafsson PM, De Jong PA, Tiddens HAWM, Lindblad A. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. *Thorax* 2008;63:129–34.
- [29] Ellemunter H, Fuchs SI, Unsinn KM, Freund MC, Waltner-Romen M, Steinkamp G, et al. Sensitivity of lung clearance index and chest computed tomography in early CF lung disease. *Respir Med* 2010;104:1834–42.
- [30] Aurora P, Gustafsson PM, Bush A, Lindblad A, Oliver C, Wallis CE, et al. Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. *Thorax* 2004;59:1068–73.
- [31] Fuchs SI, Sturz J, Junge S, Ballman M, Gappa M. A novel sidestream ultrasonic flow sensor for multiple breath washout in children. *Pediatr Pulmonol* 2008;43:731–8.
- [32] Singer F, Kieninger E, Abbas C, Yamine S, Fuchs O, Proietti E, et al. Practicability of nitrogen multiple-breath washout measurements in a pediatric cystic fibrosis outpatient setting. *Pediatr Pulmonol* 2013;48(8):739–46. <http://dx.doi.org/10.1002/ppul.22651>.
- [33] Aurora P, Bush A, Gustafsson PM, Oliver C, Wallis C, Price J, et al. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. *Am J Respir Crit Care Med* 2005;171:249–56.
- [34] Gustafsson PM, Kallman S, Ljungberg H, Lindblad A. Method for assessment of volume of trapped gas in infants during multiple-breath inert gas washout. *Pediatr Pulmonol* 2003;35:42–9.
- [35] Aurora P, Stanojevic S, Wade A, Oliver C, Kozłowska W, Lum S, et al. Lung clearance index at 4 years predicts subsequent lung function in children with cystic fibrosis. *Am J Respir Crit Care Med* 2011;183:752–8.
- [36] Robinson PD, Cooper P, Van Asperen P, Fitzgerald D, Selvadurai H. Using index of ventilation to assess response to treatment for acute pulmonary exacerbation in children with cystic fibrosis. *Pediatr Pulmonol* 2009;44:733–42.
- [37] Horsley AR, Davies JC, Gray RD, Macleod KA, Donovan J, Aziz ZA, et al. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. *Thorax* 2013;68(6):532–9.
- [38] Houlitz B, Green K, Lindblad A, Singer F, Robinson P, Nielsen KG, et al. Tidal N₂ washout ventilation inhomogeneity indices in a reference population aged 7–70 years. *European Respiratory Society*; 2012.
- [39] Sonnappa S, Bastardo CM, Wade A, Bush A, Stocks J, Aurora P. Repeatability and bronchodilator reversibility of lung function in young children. *Eur Respir J* 2013 [online ahead of print].
- [40] Keen C. Low levels of exhaled nitric oxide are associated with impaired lung function in cystic fibrosis. *Pediatr Pulmonol* 2010;45:241–8.
- [41] Pittman JE, et al. Variability of a closed, rebreathing setup for multiple breath wash-out testing in children. *Pediatr Pulmonol* 2012;47:1242–50.
- [42] Fuchs SI, et al. Calculation of the capnographic index based on expiratory molar mass–volume-curves: a suitable tool to screen for cystic fibrosis lung disease. *J Cyst Fibros* 2012;12(3):277–83.
- [43] Bakker EM, et al. Determining presence of lung disease in young children with cystic fibrosis: lung clearance index, oxygen saturation and cough frequency. *J Cyst Fibros* 2012;11(3):223–30.
- [44] Kraemer R, et al. Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis. *Respir Res* 2006;7:138.
- [45] Kraemer R, et al. Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis. *Am J Respir Crit Care Med* 2005;171:371–8.
- [46] Kraemer R, et al. Long-term gas exchange characteristics as markers of deterioration in patients with cystic fibrosis. *Respir Res* 2009;10:106.
- [47] Fuchs SI, et al. Short-term effect of physiotherapy on variability of the lung clearance index in children with cystic fibrosis. *Pediatr Pulmonol* 2010;45:301–6.
- [48] Kieninger E, et al. Long-term course of lung clearance index between infancy and school-age in cystic fibrosis subjects. *J Cyst Fibros* 2011;10(6):487–90.
- [49] Sinhal S, et al. Reproducibility of multiple breath washout indices in the unsedated preterm neonate. *Pediatr Pulmonol* 2010;45:62–70.
- [50] Hülskamp G, et al. Association of prematurity, lung disease and body size with lung volume and ventilation inhomogeneity in unsedated neonates: a multicentre study. *Thorax* 2009;64:240–5.

- [51] Riedel T, et al. Regional and overall ventilation inhomogeneities in preterm and term-born infants. *Intensive Care Med* 2009;35:144–51.
- [52] Schulzke SM, et al. Nasal versus face mask for multiple-breath washout technique in preterm infants. *Pediatr Pulmonol* 2008;43:858–65.
- [53] Latzin P, et al. Lung volume, breathing pattern and ventilation inhomogeneity in preterm and term infants. *PLoS One* 2009;4(2):e4635.
- [54] Fuchs SI, et al. Multiple breath washout with a sidestream ultrasonic flow sensor and mass spectrometry: a comparative study. *Pediatr Pulmonol* 2006;41:1218–25.
- [55] Riedel T, Richards T, Schibler A. The value of electrical impedance tomography in assessing the effect of body position and positive airway pressures on regional lung ventilation in spontaneously breathing subjects. *Intensive Care Med* 2005;31:1522–8.
- [56] Fuchs SI, et al. Lung clearance index: normal values, repeatability, and reproducibility in healthy children and adolescents. *Pediatr Pulmonol* 2009;44:1180–5.
- [57] Macleod KA, et al. Ventilation heterogeneity in children with well controlled asthma with normal spirometry indicates residual airways disease. *Thorax* 2009;64:33–7.
- [58] Sonnappa S, et al. Symptom-pattern phenotype and pulmonary function in preschool wheezers. *J Allergy Clin Immunol* 2010;126:519–26.
- [59] Gronkvist M, Bergsten E, Gustafsson P. Effects of body posture and tidal volume on inter- and intraregional ventilation distribution in healthy men. *J Appl Physiol* 2002;92:634–42.
- [60] Shao H, et al. Moment analysis of multibreath nitrogen washout in healthy preterm infants. *Pediatr Pulmonol* 1998;25:52–8.
- [61] Hjalmarson O, Sandberg K. Abnormal lung function in healthy preterm infants. *Am J Respir Crit Care Med* 2002;165:83–7.
- [62] Verbanck S, et al. Ventilation heterogeneity in the acinar and conductive zones of the normal ageing lung. *Thorax* 2013 [in press].
- [63] Downie S, et al. Ventilation heterogeneity is a major determinant of airway hyperresponsiveness in asthma, independent of airway inflammation. *Thorax* 2007;62:684–9.
- [64] Arborelius M, Rosberg HE, Wiberg R. Multiple breath nitrogen dead space. *Clin Physiol* 1988;8:561–76.
- [65] Chakr VC, et al. Ventilation homogeneity improves with growth early in life. *Pediatr Pulmonol* 2011.
- [66] Aljassim F, et al. A whisper from the silent lung zone. *Pediatr Pulmonol* 2009;44:829–32.
- [67] Davis SD, et al. Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints. *Am J Respir Crit Care Med* 2010;182(11):1387–97.